Pharmacy Practice

Joint Statement from National Hospital and Pharmacist Associations on PhRMA-Led Proposal to Restrict 340B Eligibility

Published: March 20, 2023
ASHP Press Release

Hospital and pharmacist advocates for safety-net health care and affordable prescription drugs are united in their firm opposition to a misguided effort by the drug industry and some community health centers that would restrict access to the 340B drug pricing program.

The groups – 340B Health, the American Hospital Association (AHA), the American Society of Health-System Pharmacists (ASHP), America’s Essential Hospitals (AEH), the Association of American Medical Colleges (AAMC), the Catholic Health Association of the United States, and the Children’s Hospital Association – today voiced their opposition to a campaign by the Pharmaceutical Research and Manufacturers of America (PhRMA), the National Association of Community Health Centers (NACHC), and other groups to make legislative cuts to the 340B program. The proposed changes would cause massive harm for patients who rely on hospitals that use 340B savings to provide crucial care, services, and programs to their communities.

The PhRMA-led group, deceptively branded as an effort to save 340B, proposes to remove many hospitals from the program and significantly narrow its scope of eligible drugs and patients. The proposal would only save drug company profits by reducing their already modest financial contribution to the health care safety net. 

Hospitals are critical components of the health care safety net, and they work with community health care providers to deliver a wide range of care to patients in need. Without access to 340B discounts, it will be more difficult for patients to receive the same level of care from their community health providers. These include patients whose health conditions have advanced to the point of requiring the specialized, complex care only hospitals can provide. Because 340B cuts would leave fewer hospital resources to help pay for uncompensated and unreimbursed care, this proposal would be especially harmful to patients who are uninsured, underinsured, and dependent on public health programs, such as Medicaid.

This effort is the latest development in a multiyear campaign by the drug industry to cut 340B eligibility and walk away from its commitment to support patients in need. Twenty-one drug companies already have imposed harmful restrictions on access to 340B drugs through community and specialty pharmacies, and the new proposal would limit patients’ access to discounted drugs even more.

340B Health, AHA, ASHP, AEH, AAMC, the Catholic Health Association, and the Children’s Hospital Association will continue fighting back against these drug company attacks on a proven and effective health care program for patients and communities in need.




Media Contacts:

David Glendinning
Senior Director of Communications
340B Health
[email protected]

Colin Milligan
Senior Director of Media Relations
American Hospital Association
[email protected]

Amy Ruth Cole
Senior Director of Strategic Communications and Content
American Society of Health-System Pharmacists
[email protected]

Carl Graziano
Senior Director of Communications
America’s Essential Hospitals
[email protected]

John Buarotti
Senior Specialist, Public Relations
Association of American Medical Colleges
[email protected]

Brian Reardon
Vice President of Communications and Marketing
Catholic Health Association of the United States
[email protected]

Elleni Almandrez
Director of Advocacy and Communications
Children’s Hospital Association
[email protected]

Posted March 20, 2023

Advance Your Professional Development

View Other Products

Free Board Exam Prep Resources

The Review & Recertification Reward Program (RRRP) includes free access to exam preparation material + enrollment in a recertification plan billed monthly ($10) during your initial recertification cycle. For ASHP members only.

Learn More
Review & Recertification Reward Program (RRRP)

New Edition Available to Order

AHFS Drug Information® 2024 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Order Today
AHFS 2024 Drug Information